GLP-1 drugs transform treatment for obesity and diabetes

GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, are transforming the treatment of obesity, diabetes, cardiovascular, and kidney diseases. These medications have significantly increased the market value of manufacturers like Novo Nordisk and Eli Lilly, adding approximately $1 trillion in market value since 2021. While initially approved for diabetes, their efficacy in treating obesity has led to high demand, particularly in the United States, where one in eight adults has used GLP-1 drugs.

Beyond metabolic health, research is exploring the potential of these drugs to treat Alzheimer's disease and combat drug addiction. The widespread use of these treatments is expected to have profound implications for the global economy and society, with the potential to improve the lives of over one billion people as they become more affordable and accessible.

Public figures have also commented on their use. James Corden shared that Ozempic was ineffective for him because his eating habits were not driven by hunger. Similarly, Kelly Clarkson disclosed that she uses weight loss medication to manage health issues related to her thyroid, clarifying that her specific medication is not Ozempic.